Acute Coronary Syndromes increased post-COVID-19 with NSTEMI rising dramatically by 160% in 2023 and STEMI initially increasing 50% then decreasing 50% in 2023.
Hospital admissions for ACS, particularly NSTEMI, have significantly increased in the post-COVID-19 period compared to the initial pandemic phase.
Absolute Event Rate: 0% vs 0%
Abstract Background A significant decrease of hospitalizations for Acute Coronary Syndromes (ACS) was worldwide observed during covid-19 pandemic. Special public restrictions and lockdowns as well as hospital overloading with covid-19 cases may have discouraged patients with ACS to seek for help and access emergency room for consultation. At present, there is no robust observational data reported regarding the current prevalence of ACS, in the post covid-19 era. Methods We conducted a retrospective single center analysis of all comers with ACS presented in a Greek tertiary Primary PCI center during and post covid-19 pandemic. We systematically recorded all admissions and referrals of patients with ACS submitted to an invasive coronary angiography in our institution from March 2020 till March 2024. Annual prevalence of ACS (both STEMI and NSTEMI) in our hospital was then calculated. Results As compared to the first year of the pandemic a gradual and significant increase of ACS was observed. The mean annual rate of increase was ~29% which was principally driven by NSTEMI increase (Figure 1). For STEMI, a comparable annual increase of about 50% was found during 2021 and 2022 with a sharp decrease by 50% in 2023 as compared to 2021/2022. Interestingly, after a negligible increase of NSTEMI by ~10% in 2021, a dramatic rise in 2022 (80%) and especially in 2023 (160%) was noticed (Figure 2). Conclusions Our study shows elegantly a significant increase of ACS (both STEMI and NSTEMI) in the post covid-19 period. Further investigations to fully elucidate the etiology of our findings are warranted.
Ntalianis et al. (Sat,) reported a other. Acute Coronary Syndromes increased post-COVID-19 with NSTEMI rising dramatically by 160% in 2023 and STEMI initially increasing 50% then decreasing 50% in 2023.